Edgewise submits STRATUS-HCM Phase 3 protocol after favorable FDA End-of-Phase 2 meeting

Edgewise Therapeutics says it held a favorable End-of-Phase 2 meeting with the FDA for EDG-7500, its investigational drug for symptomatic obstructive and nonobstructive hypertrophic cardiomyopathy, and has submitted the STRATUS-HCM Phase 3 protocol incorporating a tolerability-based dose escalation strategy.

Detected & updated continuously · Source: Nebula